Q3 Earnings Estimate for ImmunityBio Issued By HC Wainwright

ImmunityBio, Inc. (NASDAQ:IBRX) – Equities research analysts at HC Wainwright reduced their Q3 2026 earnings estimates for shares of ImmunityBio in a research report issued on Monday, November 9th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.18) per share for the quarter, down from their prior forecast of ($0.06). HC Wainwright currently has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for ImmunityBio’s Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.52) EPS, Q1 2027 earnings at ($0.19) EPS, Q2 2027 earnings at ($0.19) EPS, Q3 2027 earnings at ($0.18) EPS, Q4 2027 earnings at ($0.18) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.02) EPS, FY2029 earnings at $0.51 EPS and FY2030 earnings at $1.28 EPS.

IBRX has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday, October 6th. Piper Sandler reaffirmed an “overweight” rating and set a $16.00 price objective on shares of ImmunityBio in a research report on Wednesday, October 14th. Finally, Jefferies Financial Group increased their price objective on shares of ImmunityBio from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, ImmunityBio presently has an average rating of “Moderate Buy” and an average target price of $16.00.

ImmunityBio Trading Down 5.2%

NASDAQ IBRX opened at $6.74 on Wednesday. The company has a market cap of $7.14 billion, a price-to-earnings ratio of -6.24 and a beta of 0.17. The company has a 50 day moving average of $8.70 and a 200-day moving average of $7.96. ImmunityBio has a 1-year low of $1.95 and a 1-year high of $12.43.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Markowski Investments acquired a new position in ImmunityBio during the second quarter worth about $29,000. Compass Wealth Management LLC bought a new stake in shares of ImmunityBio during the 3rd quarter valued at approximately $29,000. GAMMA Investing LLC grew its holdings in shares of ImmunityBio by 262.2% during the 3rd quarter. GAMMA Investing LLC now owns 3,807 shares of the company’s stock valued at $36,000 after purchasing an additional 2,756 shares during the last quarter. Geneos Wealth Management Inc. increased its position in ImmunityBio by 579.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 5,754 shares of the company’s stock worth $44,000 after purchasing an additional 4,907 shares in the last quarter. Finally, Western Wealth Management LLC acquired a new position in ImmunityBio during the 1st quarter worth approximately $44,000. Institutional investors own 8.58% of the company’s stock.

Insider Buying and Selling at ImmunityBio

In other news, Director Barry J. Simon sold 25,000 shares of ImmunityBio stock in a transaction on Monday, October 5th. The stock was sold at an average price of $10.75, for a total value of $268,750.00. Following the transaction, the director owned 2,777,788 shares in the company, valued at approximately $29,861,221. This trade represents a 0.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 81,056 shares of the business’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $10.50, for a total value of $851,088.00. Following the transaction, the director directly owned 100,309 shares of the company’s stock, valued at $1,053,244.50. This trade represents a 44.69% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 66.10% of the stock is owned by corporate insiders.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ANKTIVA plus BCG met the primary endpoint in a randomized trial for BCG-naïve, high-grade non-muscle-invasive bladder cancer, supporting the treatment’s potential in an additional patient group. Article: ANKTIVA trial results
• Positive Sentiment: The company reported expanded FDA approval and additional international approval for ANKTIVA plus BCG, broadening its commercial opportunity. Article: Q3 results and approvals
• Neutral Sentiment: Third-quarter product revenue rose 53% year over year to about $48.7 million, while U.S. revenue for the first nine months increased 92%. However, quarterly sales declined from the prior quarter. Article: Q3 results
• Negative Sentiment: Results missed estimates: ImmunityBio reported a loss of about $0.09 per share versus an expected $0.07 loss, and revenue of about $48.8 million versus forecasts of $59.2 million. A wider loss, rising expenses, and the sequential sales decline weighed on sentiment. Article: Q3 earnings miss
• Negative Sentiment: The company disclosed “substantial doubt” about its ability to continue operating without additional funding, raising concern about potential financing or dilution. Its valuation relative to sales may also leave little room for execution setbacks. Article: Earnings, valuation, and funding concerns

About ImmunityBio

ImmunityBio is a biotechnology company that develops immunotherapies for cancer and infectious diseases. Its research combines approaches including immune-modulating biologics, cell therapies and vaccine-based treatments, with a focus on activating the body’s natural and adaptive immune responses. The company’s lead product, Anktiva (nogapendekin alfa inbakicept-pmln), received U.S. Food and Drug Administration approval in 2024 for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.